文献速递血栓与止血

经皮超声介导的基因递送进入犬肝脏可实现治疗水平的因子VIII表达

Transcutaneous ultrasound-mediated gene delivery into canine livers achieves therapeutic levels of factor VIII expression.
PubMed 文献 · Blood Adv · 2022-01-01

研究采用微泡联合经皮超声介导基因递送(UMGD)策略,将高表达肝特异性人因子VIII(hFVIII)质粒经球囊导管在透视引导下注入4只犬肝静脉,同时靶向特定肝叶行经皮UMGD治疗。4只犬均达到治疗水平的hFVIII表达,其中3只在60天实验期内维持可检测水平,质粒拷贝数与hFVIII抗原水平相关,治疗后肝损伤轻微且快速恢复。

要点

  • 4只犬均经肝靶向经皮UMGD达到治疗水平hFVIII表达。
  • 3只犬在60天实验期内hFVIII维持可检测水平。
  • 肝转氨酶和组织学显示肝损伤轻微且治疗后快速恢复。

核心结论

  • 肝靶向经皮UMGD有望成为血友病A及其他疾病的临床可行疗法。

研究设计与样本

  • 在4只犬肝脏中开展经皮超声介导基因递送(UMGD)联合微泡(MBs)增强基因转移的研究。

主要发现

  • 4只犬均达到治疗水平的hFVIII表达,其中3只在60天实验期内维持可检测水平。
  • 质粒拷贝数与hFVIII抗原水平相关,治疗肝组织中检测到质粒来源的信使RNA(mRNA)。
  • 肝转氨酶水平和组织学分析显示肝损伤轻微且治疗后快速恢复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A safe, effective, and inclusive gene therapy will significantly benefit a large population of patients with hemophilia. We used a minimally invasive transcutaneous ultrasound-mediated gene delivery (UMGD) strategy combined with microbubbles (MBs) to enhance gene transfer into 4 canine livers. A mixture of high-expressing, liver-specific human factor VIII (hFVIII) plasmid and MBs was injected into the hepatic vein via balloon catheter under fluoroscopy guidance with simultaneous transcutaneous UMGD treatment targeting a specific liver lobe. Therapeutic levels of hFVIII expression were achieved in all 4 dogs, and hFVIII levels were maintained at a detectable level in 3 dogs throughout the 60-day experimental period. Plasmid copy numbers correlated with hFVIII antigen levels, and plasmid-derived messenger RNA (mRNA) was detected in treated livers. Liver transaminase levels and histology analysis indicated minimal liver damage and a rapid recovery after treatment. These results indicate that liver-targeted transcutaneous UMGD is promising as a clinically feasible therapy for hemophilia A and other diseases.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Manson MA, Zhang F, Novokhodko A, et al. Transcutaneous ultrasound-mediated gene delivery into canine livers achieves therapeutic levels of factor VIII expression. Blood Adv. 2022. PMID: 35427415. doi:10.1182/bloodadvances.2021006016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。